Dr. Reddy’s Laboratories has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules in the US market.
Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Dr. Reddy’s Laboratories has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules in the US market.
One of the world’s most in-demand anaesthetics can now be produced on the spot, thanks to the thermos-flask sized device that recently won Flinders University inventor Professor Colin Raston an Ig Nobel prize.
Researchers report that if you are generally positive about life and inspires others too to lead a happy life, chances are that you harbor a special set of brain connections not found in people with negative thoughts. The paper appeared in the journal Nature Neuroscience.
A new study says that the work and achievements of men tend to be evaluated as more creative than similar work and achievements produced by women. The study was published in the journal Psychological Science.
Researchers from Georgia State University reports that monkeys perceive visual illusions in the same way as apes and humans see them in their daily life. The findings were published in the Journal of Experimental Psychology: Animal Learning and Cognition.
Researchers have found that having suicidal thoughts need not necessarily depression it could be obstructive sleep apnea, (OSA), which is a common sleep disorder. The findings appeared in the Journal of Clinical Sleep Medicine.
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age. More than 300 families from across Canada participated in this research through the Canadian Healthy Infant Longitudinal Development (CHILD) Study.
Merck, known as MSD outside the United States and Canada announce the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) monotherapy, the company’s anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg every three weeks, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. Under FDA’s accelerated approval regulations, this indication for KEYTRUDA is approved based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
[adsense:336x280:8701650588]
Researchers from Stockholm University, in international collaboration with UK and Japan, has reached a breakthrough in understanding how fructose is transported into our cells. This could be a potential benefit for the development of novel treatments against some forms of cancer, obesity and diabetes. The results are published as an article in the scientific journal Nature.
WHO cautioned that "indiscriminate" use of antibiotics is increasingly leading to resistance to medicines and treatment failure even as it asked India and South East Asian nations to "urgently" address this threat to public health.